Publications by authors named "Thomas Xavier"

Claim this Profile
T
The continuing search for effective treatments for older adults with acute myeloid leukemia.
Xavier Thomas

Expert Rev Clin Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Promising Drugs Targeting Specific Mechanisms of Deregulation in T Cell Lineage Acute Lymphoblastic Leukemia.
Xavier Thomas

Oncol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia.
Xavier Thomas

Curr Oncol Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining the safety and efficacy of imetelstat in low-risk myelodysplastic syndrome.
Xavier Thomas

Expert Opin Pharmacother· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.
Thomas Cluzeau, Fabio Guolo, Edmond Chiche, Paola Minetto, Ramy Rahme, Xavier Thomas

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.
Yves Chalandon, Philippe Rousselot, Sylvie Chevret, Jean-Michel Cayuela, Rathana Kim, Xavier Thomas

Blood· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is There any Relationship Between the Repeated Complications of Sickle Cell Disease and the Potential Development of Acute Leukemia?
Giovanna Cannas, Mohamed Elhamri, Xavier Thomas

Oncol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Pierre Hirsch, Jérôme Lambert, Maxime Bucci, Caroline Deswarte, Augustin Boudry, Xavier Thomas

Blood Cancer J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Gail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, Karen Yee, Hagop Kantarjian, Xavier Thomas

Blood Adv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Ludovic Gabellier, Pierre Peterlin, Sylvain Thepot, Yosr Hicheri, Franciane Paul, Xavier Thomas

Ann Hematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation.
Xavier Thomas

Oncol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study.
Corentin Orvain, Sylvain Chantepie, Xavier Thomas, Martine Escofrre-Barbe, Francoise Huguet

Haematologica· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
Jorge Sierra, Pau Montesinos, Xavier Thomas, Laimonas Griskevicius, Thomas Cluzeau

Blood Adv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Pierre Fenaux, Marco Gobbi, Patricia L Kropf, Jean-Pierre J Issa, Gail J Roboz, Xavier Thomas

Blood Adv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
Stéphane de Botton, Pierre Fenaux, Karen Yee, Christian Récher, Andrew H Wei, Xavier Thomas

Blood Adv· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sickle cell disease and acute leukemia: one case report and an extensive review.
Giovanna Cannas, Solène Poutrel, Maël Heiblig, Hélène Labussière, Marie-Virginie Larcher, Xavier Thomas

Ann Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Stéphane de Botton, Pau Montesinos, Andre C Schuh, Cristina Papayannidis, Paresh Vyas, Xavier Thomas

Blood· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Grégoire Le Meur, Adriana Plesa, Marie-Virginie Larcher, Gaëlle Fossard, Fiorenza Barraco, Xavier Thomas

Transplant Cell Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development.
Xavier Thomas

Expert Opin Investig Drugs· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
Nicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, Rathana Kim, Julie Rieunier, Xavier Thomas

Blood· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
Amer M Zeidan, Pierre Fenaux, Marco Gobbi, Jiří Mayer, Gail J Roboz, Xavier Thomas

Blood· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor-Derived Leukemia in a Recipient of Double-Unit Cord Blood Transplantation for Acute Myeloid Leukemia: A Case Study and Literature Review.
Adriana Plesa, Isabelle Tigaud, Sandrine Hayette, Christophe Roumier, Xavier Thomas

Oncol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials.
Xavier Thomas, Mohamed Elhamri, Alexandre Deloire, Maël Heiblig

Expert Opin Emerg Drugs· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.
Mauricette Michallet, Mohamad Sobh, Stephane Morisset, Alexandre Deloire, Emmanuel Raffoux, Xavier Thomas

Clin Lymphoma Myeloma Leuk· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study.
Nicolas Boissel, Patrice Chevallier, Vadim Doronin, Laimonas Griskevicius, Alexey Maschan, Xavier Thomas

Cancer Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis